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Abstract
To evaluate renal side-effects of anti-epileptic medication by valproate (VPA) and carbamazepine (CBZ), we
performed a prospective study to assess renal tubular function by measuring N-acetyl-b glucosaminidase (NAG)/Cr
activity index in epileptic children. The study was conducted on 112 children who were diagnosed with epilepsy
(28 patients were observed before treatment with anti-epileptics, 28 children were administered VPA, 28 children
were treated with CBZ, and 28 healthy children were selected age &sex matched for). An especial NAG assay kit
was used for quantitative measuring of NAG in patient urine samples. The patients receiving VPA exhibited higher
rate of NAG activity compared with the two groups which not receiving anti-epileptic drugs. Measurement of
urinary NAG/Cr index in the children who received CBZ also, was significantly higher than those who were not
administered anti-epileptic drugs. The measurement of NAG/Cr index in the VPA group was significantly higher
than that in the CBZ group (NAG index: 2.75 versus 1.71). Children on anti-epileptic treatment with VPA or CBZ
might demonstrate signs of renal tubular dysfunction, reflected by NAG/Cr activity index. This side effect can be
potentially more occurred following VPA administration.
Introduction
The use of common antiepileptic drugs can potentially
result in some toxic reactions such as dermatitis, nephri-
tis, hepatitis, as well as severe anemia. Some of these
impairments are characterized by the changes of
enzymes that one of the most applicable enzymes
secreted in urine is N-acetyl-b glucosaminidase (NAG)
that its activity is considered as a sensitive marker for
diagnosis of renal tubular impairment in various disease
states and its clinical diagnostic efficiency has been
approved in some researches [1,2]. NAG is a hydrolytic
enzyme with a molecular weight of 130,000 to 140,000
daltons. It is normally not filtered at the glomerulus.
NAG is a widely distributed lysosomal enzyme, located
predominantly in the renal proximal tubules [3]. It has
previously been reported that NAG activity in rat urine
increases after exposure to nephrotoxic agents in animal
models [4]. Recently, increased excretion of urinary
NAG in patients who were treated with valproate (VPA)
and carbamazepine (CBZ) has been also suggested in
some human trials [5-7]. However, some others revealed
that the increased excretion of tubular enzymes and
proteins in children with epilepsy is most probably not
due to side-effect of the anti-epileptic drugs, but to a
physiological alteration associated with the epilepsy itself
[8]. Totally, it seems that the influence of epilepsy itself
or its therapeutic antiepileptic regimen on stimulating
activity of urinary indicator enzymes and thus renal
damages via increasing of this enzyme is already
unknown. The aim of this study was to assess the effect
of some antiepileptic drugs (VPA and CBZ) on NAG
activity measured by NAG/Cr activity index in epileptic
children. In fact, our study endpoint was to measure
urinary NAG/Cr index in the children who received
CBZ or VPA. Then we compared increased excretion of
tubular NAG enzyme in children treating these common
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anti-epileptic treatment regimens and compared it with
those who were not administered anti-epileptic drugs.
Methods
Study population
The study was conducted on 112 children (63 boys and
49 girls, mean age 8.30 ± 2.50 years, range 3-16 years)
who were recently referred to the neurology clinic of
Fatemieh hospital in Semnan and diagnosed with epi-
lepsy. Child with the signs of renal dysfunction and
those with the previous history of diabetes mellitus or
liver diseases were excluded. Study children were
divided into four groups: 1) the patients with the final
diagnosis of epilepsy, but did not receive antiepileptic
treatments (n = 28); 2) those with confirmed epilepsy
received VPA (n = 28); 3) the patients with epilepsy
treated with CBZ (n = 28); and 4) the control group
consisted of 28 healthy children. The course of VPA
varied between 6 and 48 months with an average of 20.5
± 11.2 months. The VPA doses given to the patients
were a minimum of 15 mg/kg/day, maximum 25 mg/kg/
day, with an average of 20 ± 3 mg/kg/day. Also, the
course of CBZ varied between 6 and 48 months with an
average of 21.7 ± 12.6 months. The CBZ doses given to
the patients were a minimum of 10 mg/kg/day, maxi-
mum 30 mg/kg/day, with an average of 24 ± 4 mg/kg/
day. The mean duration of the two antiepileptic treat-
ments was not different. None of the epileptic and
healthy children were taking medication at the time of
urine sampling. Study protocol was performed according
to the principles of the Declaration of Helsinki and
approved by the ethics committee of the Semnan Uni-
versity of Medical Sciences. Written informed consent
was obtained from all parents.
NAG evaluation
A 10 mL aliquot of urine collected after the first morn-
ing void was used for assay of urine creatinine and the
enzyme. NAG activity was assessed by NAG/Cr ratio
measuring. An especial NAG assay kit (using the Boeh-
ringer Mannheim kits, Germany) was used for the quan-
titative in vitro determination of NAG in patient urine
samples. In this assay, it was used a specific substrate, 2-
methoxy-4-(2’nitrovinyl)-phenyl 2-acetamido-2-deoxy-b-
D-glucopyranoside (MNP-GlcNAc) that is hydrolyzed by
NAG to produce 2-methoxy-4-(2’-nitrovinyl)-phenol
product. The product formation is detected at 505 nm
upon addition of an alkaline buffer. Blood creatinine
levels were determined using an Olympus 5241 appara-
tus (Hamburg, Germany).
Statistical analysis
Results were reported as mean ± standard deviation
(SD) for the quantitative variables and percentages for
the categorical variables. The groups were compared
using the Mann Whitney U test for the continuous vari-
ables and the chi-square test (or Fisher’s exact test if
required) for the categorical variables. P values of 0.05
or less were considered statistically significant. All the
statistical analyses were performed using SPSS version
16.0 (SPSS Inc., Chicago, IL, USA) for Windows.
Results
As shown in Table 1, there were no differences in male
to female ratio as well as mean age across the four
study groups. The NAG activity, assessed by the NAG/
Cr index measurement in the groups of healthy chil-
dren, patients group before receiving anti-epileptic ther-
apy, and patients who received CBZ or VPA is
presented in Figure 1. There is no significant difference
in NAG activity between the control group and another
non-treatment group (NAG index: 0.68 versus 0.73, p =
0.611). However, the patients who were receiving VPA
exhibited higher rate of NAG activity compared with
the two groups which not receiving anti-epileptic drugs
(p < 0.001). Also, measurement of urinary NAG/Cr
index in the children who received CBZ was signifi-
cantly higher than those who were not administered
anti-epileptic drugs (p < 0.001). Mean plasma concentra-
tions of VPA and CBZ in these two treated patient
groups were 68.7 ± 17.4 μg/mL and 5.4 ± 1.2 μg/mL,
respectively. There was a significant correlation between
the serum concentration of VPA and urinary NAG
levels (r = 0.39, P < 0.01). There was also a significant
correlation between the serum concentration of CBZ
and NAG excretion (r = 0.46, P < 0.01). Regarding rela-
tionship between the duration of treatment and NAG
index, this correlation was significant in the patients
who received VPA (r = 0.56, P < 0.01) as well as in
those who received CBZ treatment (r = 0.36, P < 0.01).
With regard to the difference in NAG/Cr index
between the two treated groups, measurement of this
index in the VPA group was significantly higher than
that in the CBZ group (NAG index: 2.75 versus 1.71, p
< 0.001). In each study group, the mean NAG/Cr
index was statistically similar between the two genders
(Table 2).
Table 1 Baseline characteristics of four study groups
Study group Number Male/female ratio Age
Mean SD
Control group 28 16/12 8.29 3.68
Before treatment 28 15/13 8.36 3.91
Valproate group 28 16/12 8.43 3.61
Carbamazepine group 28 16/12 8.14 3.34
P-value 0.998 0.979
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Discussion
Current study could confirm previous reports about an
increased excretion of tubular NAG enzyme in children
treating common anti-epileptic treatment regimens. Our
study showed that mean value of NAG/Cr index was
increased 3.7-fold following administration of VPA over
the median values of the epileptic children before treat-
ment. Elevation of this index after the treatment with
CBZ was 2.3-fold following administration of VPA over
the median values of epileptic ones before treatment.
However, the measure of NAG/Cr index was not signifi-
cantly different between the two untreated groups. The
adverse impact of mono and combined therapies on
NAG/Cr index and therefore on renal tubular function
has been observed in several previous studies, while
some others demonstrated the clinical efficiencies of
these drugs in epileptic children. In a study by Otsuka
et al. the level of urinary excretion of NAG was high in
29% of all patients, in 47% of VPA group, and in 38% of
CBZ group. In their study, a significant positive correla-
tion was observed between NAG/Cr index and serum
concentration of VPA [9]. In another study by Tseng et
al. VPA administration was accompanied with the high-
est incidence of abnormal urinary NAG/Cr index (in
about 78% of treated children) that was significantly
higher than that in the CBZ group with the incidence of
26%. However, the incidence of high urinary NAG index
in the poly-therapy group and that in mono-therapy
group was significantly similar [10]. These adverse
effects were also approved in studies on animal models.
Some experimental studies revealed high NAG level in
rats with partial ureteral obstruction and hydronephrotic
atrophy [11,12]. Contrarily, in Hurkacz et al. study,
increasing of NAG/Cr activity index was shown with
concomitant therapy, but that was in the normal range
and therefore tubular dysfunction was not approved
Figure 1 NAG index measurement in four study groups (presented as mean ± SD)
Table 2 Comparison of the NAG index measurement between the two genders in each group







Control group 0.68 ± 0.34 *† 0.73 ± 0.39*† 0.61 ± 0.25*† 0.332
Before treatment 0.74 ± 0.35 0.66 ± 0.36 0.80 ± 0.34 0.300
Valproate group 2.75 ± 0.48* 2.43 ± 0.52* 2.48 ± 0.43* 0.783
Carbamazepine group 1.71 ± 0.46† 1.69 ± 0.39† 1.74 ± 0.55† 0.791
Data are presented as mean ± SD
* and † indicate significant intergroup differences (p < 0.001)
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following their treatment schedule [7]. Also, in another
study by Korinthenberg et al. those on anti-epileptic
treatment with therapeutic drug levels demonstrated
minor signs of tubular dysfunction [13]. In earlier inves-
tigations, it has been hypothesized that following admin-
istration and absorption of some anti-epileptic drugs,
the lysosomal contents of the tubular cells might be
secreted into the lumen of the urinary tract to eliminate
indigestible residues that are left after hydrolysis of high
molecular weight material recaptured from the glomeru-
lar filtrate [14]. In addition, NAG is a lysosomal hydro-
lasis that plays an important role in the catabolism of
both glycoproteins and glycosaminoglycans [15-17]. This
mechanism is mainly occurred in the proximal tubulus
and therefore can be interpreted as an indicator of func-
tional disturbance of tubuls [13]. Thus, according to our
study results as well as other previous findings, NAG/Cr
index can be used as a sensitive indicator of renal tubu-
lar disease activity, and it might be a suitable screening
test for early diagnosis of renal disturbance.
In our survey, duration of treatment in all study groups
was similar. It was suggested that distribution of NAG
index of patients depended significantly on the length of
therapy so that the level of urinary excretion of NAG was
significantly higher in those who were taking long-term
treatment (>10 years) with VPA, CBZ and combined
therapy than those taking therapy shorter than 10 years
[18]. Even, after 1 to 2 years of the beginning of treat-
ment, these patients may show persistence of the changes
found after 6 months of therapy [19]. Therefore, in the
necessity of long-term administrating these drugs parti-
cularly VPA in epileptic children, a suitable dose of drug
as well as appropriate treatment time should be primarily
considered for minimizing their probable side effects.
Conclusion
Based on the findings of this study, children on anti-epi-
leptic treatment with VPA or CBZ might demonstrate
signs of renal tubular dysfunction, reflected by NAG/Cr
activity index. This side effect can be potentially more
occurred following VPA administration.
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